Sofosbuvir
Sovaldi (sofosbuvir) is a small molecule pharmaceutical. Sofosbuvir was first approved as Sovaldi on 2013-12-06. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Sovaldi's patents are valid until 2030-12-11 (FDA).
| Trade Name | Sovaldi |
|---|---|
| Common Name | Sofosbuvir |
| Indication | chronic hepatitis c, hepatitis c |
| Drug Class | Phosphoro-derivatives; antivirals: RNA polymerase (NS5B) inhibitor |
